Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)─Helmholtz Centre for Infection Research (HZI), Campus E 8.1, 66123 Saarbrücken, Germany.
Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany.
Biomacromolecules. 2023 Aug 14;24(8):3742-3754. doi: 10.1021/acs.biomac.3c00424. Epub 2023 Jul 31.
Gene knockdown by siRNA offers an unrestricted choice of targets and specificity based on the principle of complementary Watson-Crick base pairing with mRNA. However, the negative charge, large molecular size, and susceptibility to enzymatic degradation of siRNA impede its successful transfection, hence limiting its potential for therapeutic use. The development of efficient and safe siRNA transfection agents is, therefore, critical for siRNA-based therapy. Herein, we developed a protein-based biodynamic polymer (biodynamer) that showed potential as a siRNA transfection vector, owing to its excellent biocompatibility, easy tunability, and dynamic polymerization under acidic environments. The positively charged biodynamers formed stable dynamic nanocomplexes (XL-DPs, hydrodynamic diameter of approximately 104 nm) with siRNA via electrostatic interactions and chemical cross-linking. As a proof of concept, the optimized XL-DPs were stable in physiological conditions with serum proteins and demonstrated significant pH-dependent size change and degradability, as well as siRNA release capability. The minimal cytotoxicity and excellent cellular uptake of XL-DPs effectively supported the intracellular delivery of siRNA. Our study demonstrated that the XL-DPs in survivin siRNA delivery enabled potent knockdown of survivin mRNA and induced notable apoptosis of carcinoma cells (2.2 times higher than a lipid-based transfection agent, Lipofectamine 2000). These findings suggested that our XL-DPs hold immense potential as a promising platform for siRNA delivery and can be considered strong candidates in the advancement of next-generation transfection agents.
siRNA 的基因敲低为基于与 mRNA 互补的 Watson-Crick 碱基配对的原理提供了无限制的靶标选择和特异性。然而,siRNA 的带负电荷、分子量大和易被酶降解的特性阻碍了其成功转染,从而限制了其在治疗中的应用潜力。因此,开发高效、安全的 siRNA 转染剂对于基于 siRNA 的治疗至关重要。在此,我们开发了一种基于蛋白质的生物动态聚合物(biodynamer),由于其出色的生物相容性、易于调节性以及在酸性环境下的动态聚合性,它显示出作为 siRNA 转染载体的潜力。带正电荷的生物动态聚合物通过静电相互作用和化学交联与 siRNA 形成稳定的动态纳米复合物(XL-DPs,约 104nm 的水动力直径)。作为概念验证,优化后的 XL-DPs 在含有血清蛋白的生理条件下稳定,表现出显著的 pH 依赖性尺寸变化和可降解性,以及 siRNA 释放能力。XL-DPs 的最小细胞毒性和优异的细胞摄取能力有效地支持了 siRNA 的细胞内递送。我们的研究表明,XL-DPs 在 survivin siRNA 递送中能够有效地敲低 survivin mRNA,并诱导癌细胞明显的细胞凋亡(比脂质体转染试剂 Lipofectamine 2000 高 2.2 倍)。这些发现表明,我们的 XL-DPs 作为一种有前途的 siRNA 递送平台具有巨大的潜力,并可以被认为是下一代转染剂发展的有力候选者。